MedPath

Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation

Phase 3
Completed
Conditions
Nutrition Support
Interventions
Other: Compounded ternary parenteral nutrition admixtures
Other: Oliclinomel N4
Registration Number
NCT01579097
Lead Sponsor
Baxter Healthcare Corporation
Brief Summary

The objective of this study is to assess the safety and efficacy of Oliclinomel N4 compared to compounded ternary parenteral nutrition (PN) admixtures for the delivery of PN in hospitalized adults for whom oral or enteral nutrition is not possible, insufficient, or contraindicated.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
458
Inclusion Criteria
  • Inpatient but hospitalized < 14 days prior to enrollment
  • Requires PN because oral or enteral nutrition is not possible, insufficient, or contraindicated
  • Has capability to complete at least 5 days of study treatment (i.e., PN)
  • Has a useable peripheral vein for delivery of intravenous (IV) PN
Exclusion Criteria
  • Has a life expectancy of < 6 days from initiation of study treatment, in the opinion of the Investigator
  • Known hypersensitivity to the components of either of the investigational study treatments
  • Use of prohibited medications (e.g. glucocorticosteroids or antitumor chemotherapeutic agents) within 30 days prior to enrollment
  • Known serious clinically significant condition that would preclude participation in the study
  • Known chronic active hepatitis, elevated liver function tests
  • Known history of human immunodeficiency virus infection
  • Known severe dyslipidemia, severe hyperglycemia,clinically significant abnormalities of plasma electrolytes
  • Known pregnancy or lactation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
compounded ternary parenteral nutritionCompounded ternary parenteral nutrition admixturescompounded ternary Parenteral Nutrition admixture
Oliclinomel N4 formulationOliclinomel N4Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
Primary Outcome Measures
NameTimeMethod
Serum PrealbuminSerum Prealbumin at Day 5
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shanghai No. 6 Hospital

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath